What's in Austin Health's pipeline?

Austin Health has 5 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Austin Health's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/austin-health.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Austin Health — Portfolio Competitive Intelligence Brief

Austin Health pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase
Administration of N2O	Administration of N2O	marketed
sevoflurane or isoflurane	sevoflurane or isoflurane	marketed
No nitrous oxide	No nitrous oxide	marketed

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Austin Health:

Cite this brief

Drug Landscape (2026). Austin Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/austin-health. Accessed 2026-05-16.